摘要
目的:分析艾司西酞普兰、舍曲林治疗高血压合并抑郁的效果,为临床治疗提供数据支持。方法:选取2018年1月-2020年1月本院门诊治疗的高血压合并抑郁的患者112例,随机将其分为艾司西酞普兰组(57例)及舍曲林组(55例),治疗6周后比较两组患者的治疗效果、治疗前后的血压水平及汉密顿抑郁量表评分(HAMD-17)、不良反应发生率。结果:治疗后,抗抑郁治疗效果方面,舍曲林组的总有效率(70.91%)与艾司西酞普兰组(84.21%)差异无统计学意义(χ^2=1.710,P=0.088);降血压治疗效果方面,舍曲林组(72.73%)明显低于艾司西酞普兰组(94.74%),差异有统计学意义(χ^2=10.219,P=0.006)。经过治疗,两组患者血压及HAMD-17评分均较治疗前有明显改善(P<0.05),艾司西酞普兰组治疗后的血压明显低于舍曲林组(P<0.05)。两组患者在治疗期间的不良反应发生情况差异无统计学意义(P>0.05)。结论:舍曲林和艾司西酞普兰对高血压合并抑郁患者的治疗效果均较好,艾司西酞普兰组效果更佳,可有效降低血压水平,改善抑郁状态,且安全性较高,值得临床应用。
Objective:To analyze the effect of Escitalopram and Sertraline in the treatment of hypertension with depression,and provide data support for clinical treatment.Method:A total of 112 patients with hypertension combined depression from January 2018 to January 2020 in our hospital outpatient treatment were brought into study and randomly divided into Escitalopram group (57 cases) and Sertraline group (55 cases).Blood pressure and Hamilton depression rating scale (HAMD-17),the incidence of adverse reactionscompare were compared after 6 weeks of treatment.Result:After treatment,there was no statistical difference in the total effective rate between the Sertraline group (70.91%) and the Escitalopram group of 84.21% (χ^2=1.710,P=0.088).In terms of the therapeutic effect of lowering blood pressure,the Sertrillin group (72.73%) was significantly lower than Escitalopram group (94.74%),the difference was statistically significant (χ^2=10.219,P=0.006).After treatment,the blood pressure and HAMD-17 scores of the two groups were significantly improved compared with those before treatment (P<0.05),and the blood pressure of the Escitalopram group after treatment was significantly lower than that of the Sertraline group (P<0.05).There was no difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Sertraline and Escitalopram can both effectively improve the depressive state in patients with hypertension complicated with depression,Escitalopram group was better in lowering blood pressure and the safety is higher,worthy of clinical application.
作者
杨永涛
崔利军
郑冬瑞
崔伟
YANG Yongtao;CUI Lijun;ZHENG Dongrui;CUI Wei(Jining Medical University,Jining 272000,China;不详)
出处
《中外医学研究》
2020年第36期14-16,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH